NeoGenomics Inc
(NAS:NEO)
$
16.66
0.46 (2.84%)
Market Cap: 2.14 Bil
Enterprise Value: 2.35 Bil
PE Ratio: 0
PB Ratio: 2.33
GF Score: 77/100 - Q2 2024 Neogenomics Inc Earnings Call TranscriptJul 29, 2024$14.64 (-1.61%)Earnings
- Q1 2024 Neogenomics Inc Earnings Call TranscriptApr 30, 2024$13.92 (-8.54%)Earnings
- Q4 2023 Neogenomics Inc Earnings Call TranscriptFeb 20, 2024$14.7 (+2.37%)Earnings
- Neogenomics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Q3 2023 Neogenomics Inc Earnings Call TranscriptNov 06, 2023$14.65 (-4.06%)Earnings
- Q2 2023 Neogenomics Inc Earnings Call TranscriptAug 08, 2023$15.32 (-3.04%)Earnings
- Neogenomics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Neogenomics Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Neogenomics Inc Earnings Call TranscriptMay 08, 2023$15.4 (+0.59%)Earnings
- Neogenomics Inc Investor Day TranscriptApr 04, 2023
- Q4 2022 Neogenomics Inc Earnings Call TranscriptFeb 23, 2023$16.63 (+24.57%)Earnings
- Q3 2022 Neogenomics Inc Earnings Call TranscriptNov 08, 2022$8.9 (+25.35%)Earnings
- Q2 2022 Neogenomics Inc Earnings Call TranscriptAug 09, 2022$11.68 (+14.17%)Earnings
- Neogenomics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q1 2022 Neogenomics Inc Earnings Call TranscriptApr 27, 2022$10.44 (-3.78%)Earnings
- Neogenomics Inc at Raymond James Institutional Investors Conference TranscriptMar 07, 2022
- Q4 2021 Neogenomics Inc Earnings Call TranscriptFeb 23, 2022$18.52 (-1.07%)Earnings
- Q3 2021 Neogenomics Inc Earnings Call TranscriptNov 04, 2021$38.35 (-17.58%)Earnings
- Q2 2021 Neogenomics Inc Earnings Call TranscriptAug 06, 2021$46.75 (-2.01%)Earnings
- Neogenomics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Neogenomics Inc Annual Shareholders Meeting TranscriptMay 27, 2021
- Q1 2021 Neogenomics Inc Earnings and to Discuss Acquisition of Inivata Ltd Call TranscriptMay 05, 2021
- Q4 2020 Neogenomics Inc Earnings Call TranscriptFeb 24, 2021$54.34 (+2.55%)Earnings
- Neogenomics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Q3 2020 Neogenomics Inc Earnings Call TranscriptOct 27, 2020$41.25 (-1.67%)Earnings
- Neogenomics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Q2 2020 Neogenomics Inc Earnings Call TranscriptJul 28, 2020$35.8 (-2.77%)Earnings
- Neogenomics Inc Annual Shareholders Meeting TranscriptMay 28, 2020
- Q1 2020 Neogenomics Inc Earnings Call TranscriptApr 28, 2020$27.97 (-7.63%)Earnings
- Q4 2019 Neogenomics Inc Earnings Call TranscriptFeb 27, 2020$27.51 (-8.27%)Earnings
- Q3 2019 Neogenomics Inc Earnings Call TranscriptOct 29, 2019$23.36 (+11.98%)Earnings
- Neogenomics Inc at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Q2 2019 Neogenomics Inc Earnings Call TranscriptJul 30, 2019$23.9 (-1.65%)Earnings
- Q1 2019 Neogenomics Inc Earnings Call TranscriptApr 30, 2019$20.83 (-0.29%)Earnings
- Neogenomics Inc at Cowen Health Care Conference TranscriptMar 12, 2019
- Q4 2018 Neogenomics Inc Earnings Call TranscriptFeb 19, 2019Earnings
Neogenomics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023 / 06:20PM GMT
Release Date Price:
$16.63
(+2.21%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
All right. It's great. Thanks, everyone, for joining us. I'm Matt Sykes for the Life Science Tools and Diagnostics Analyst at Goldman Sachs. I have the pleasure of having the senior management team from NeoGenomics here today. Chris Smith, the CEO; Jeff Sherman, the CFO; and Warren Stone, President of Clinical Services.
Chris, Jeff, Warren, thank you very much for joining us.
Christopher Michael Smith
NeoGenomics, Inc. - CEO & Director
Yes. Good to be here.
Jeffrey S. Sherman
NeoGenomics, Inc. - CFO
Thank you.
Questions & Answers
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
Maybe if we'll start out, Chris, and you guys can chime in as well, just sort of set the stage in terms of talking about first quarter results and some of the trends you're seeing in the business and what your expectations are for the second half
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)